A <scp>UK</scp> retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease

Abstract

The observed reductions in numbers of hospitalisations, surgical procedures and consultations with healthcare professionals are key indicators of the clinical effectiveness of infliximab for the treatment of CD. These benefits result in overall decreases in healthcare resource utilisation, which translate into cost savings for the NHS.